inexpensive device can be used for this test. Recent reports suggest that peak flow measurements may be an inexpensive way of screening and initial identification of severe cases of COPD for subsequent confirmatory spirometry Methods: A cross sectional analytical method of research in assessing the peak expiratory flow rate and its height ratio (PEFR/Ht2) measured by a portable device as the main tool in gathering the data.
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Results: PEF measurements resulted in a sensitivity of 77-83% and 81-88% specificity with 85%, 86% and 91% accuracy in predicting FEV1/ FVC <0.70, below the lower limit of normality and FEV1 percentage predicted of 50% and below respectively.
Conclusion: PEFR could be used as a simple tool in the primary health care setting to screen and identify severe cases of Chronic Obstructive Pulmonary Disease for subsequent spirometry. Yishen, Yiqi Zishen) on rats with chronic obstructive pulmonary disease (COPD) according to the established R-value comprehensive evaluation method.
Methods: 120 rats were randomly divided into control, model, Bufei Jianpi, Bufei Yishen, Yiqi Zishen and aminophylline groups. The COPD rat models were established by smoke inhalation and bacterial infection. Rats were gavaged with the corresponding treatments from week 9 to 20. Half of rats were left for another 12 weeks without treatment to observe the long-term effect. Indicators related to curative effect, including lung function, pathology of lung tissue and right ventricular hypertrophy index were observed. The effect was evaluated with R-value comprehensive evaluation method.
Results: From the 12th to 32nd week, three indicators related to lung function were significantly altered by Tiaobu Fei-Shen therapies and aminophylline, the relative improvement from high to low was Bufei Yishen, Yiqi Zishen, Bufei Jianpi, and aminophylline. Considering both the 20th and 32nd weeks, five indicators related to pathology of lung tissue were significantly improved in all treated groups (P < 0.01), the relative improvement from high to low was Bufei Yishen, Bufei Jianpi, Yiqi Zishen, and aminophylline. At the 20th, 32nd week, and both 20th and 32nd weeks, all eleven indicators related to curative effect were significantly improved in all treated groups (P < 0.01), especially Bufei Jianpi granule as compared with aminophylline at week 20 (P < 0.05), and Tiaobu FeiShen therapies as compared with aminophylline at both the 20th and 32nd weeks (P < 0.01, P < 0.05). The relative improvement from high to low was Yiqi Zishen, Bufei Jianpi, Bufei Yishen, and aminophylline. Objective: To compare the effectiveness of the three available inhaled LAMA/LABA combinations (glycopyrronium/indacaterol, tiotropium/olodaterol, and umeclidinium/vilanterol) in patients with COPD.
Methods:
We conducted a retrospective review of electronic medical charts of 51 patients with stable-phase COPD receiving treatment with any LAMA/LABA combination for 1 year (April 1, 2017 to March 31, 2018 . We compared changes after 12 weeks of treatment in the following clinical outcomes: various respiratory functions (FVC, FEV1, IC) modified Medical Research Council dyspnea score (mMRC), and number of exacerbations of COPD. We also compared adherence and frequency of side effects among patients receiving the three LAMA/LABA combinations.
Results: All three LAMA/LABA combination agents showed similar improvement in respiratory function and mMRC score. See figure, there was no statistically significant difference in the improvement between the three groups. P < 0.05 Similarly, there were no differences in adherence, number of exacerbations of COPD, and frequency of side effects between the three groups.
Conclusion:
The three currently available inhaled LAMA/LABA combination drugs showed similar improvement in respiratory function and mMRC score in patients with COPD.
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